Lucy Hynds Karnell

Lucy Hynds Karnell

Auto-generated profile, based on publicly available information

Lucy Hynds Karnell

Department of Otolaryngology—Head and Neck Surgery, University of Iowa Health Care, 200 Hawkins Drive, Iowa City, Iowa 52242

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2000 in Head & Neck
Verified
Journal Article
Closed access
PDF file
BKBrenton B. Koch
Brenton B. Koch
LKLucy H. Karnell
Lucy H. Karnell
HHHenry T. Hoffman
Henry T. Hoffman
LALouis W. Apostolakis
Louis W. Apostolakis
RRRobert A. Robinson
Robert A. Robinson
HMHerman R. Menck
Herman R. Menck

4 September 2003 in Cancer
Verified
Journal Article
Open access
PDF file
RSRussell B. Smith
Russell B. Smith
LALouis W. Apostolakis
Louis W. Apostolakis
LKLucy H. Karnell
Lucy H. Karnell
BKBrenton B. Koch
Brenton B. Koch
RRRobert A. Robinson
Robert A. Robinson
HHHenry T. Hoffman
Henry T. Hoffman
BACKGROUND: Osteosarcoma is the most common primary bone malignancy overall but is encountered infrequently in the head and neck. Limited data are available on the significance of prognostics factors and results of therapy for patients with head and neck osteosarcoma (HNOS). It is known that surgical therapy is critical to successful outcome. The impact of adjuvant chemotherapy has not been defined well.METHODS: The National Cancer Data Base has collected data on cases of HNOS by voluntary accrual from participating hospitals. This database was used to assess patient demographics, tumor characteristics, treatment, and outcome for an 11‐year period extending from 1985 to 1996.RESULTS: The data set contained 496 cases of HNOS. Overall, the 5‐year disease‐specific survival rate was 59.7%. Factors associated with a poor prognosis were age older than 60 years; nonmandibular tumor location; tumor size > 6 cm; histologic type of osteoblastic, not otherwise specified (NOS); advanced disease stage; nonsurgical initial therapy; and positive margins of resection. Increased use of multimodality therapy was noted during the later years of the study. No substantial difference in the 5‐year survival rate was noted between treatment with surgery alone (74.7%) and surgery with adjuvant chemotherapy (71.3%), despite the greater prevalence of tumors with poor prognostic factors in the surgery and adjuvant chemotherapy group.CONCLUSIONS: Surgery with clear margins is an important factor in successful therapy for patients with HNOS. Improved survival has been noted within the last 2 decades compared with historic controls. Multiple negative prognostic factors have been identified and should be considered in treatment planning. The role of chemotherapy has not been defined well, but its incorporation into treatment of patients with high‐risk tumors may improve survival. Cancer 2003. © 2003 American Cancer Society.DOI 10.1002/cncr.11716

30 November 2005 in Head & Neck
Verified
Journal Article
Closed access
PDF file
LKLucy Hynds Karnell
Lucy Hynds Karnell
GFGerry F. Funk
Gerry F. Funk
ACAlan J. Christensen
Alan J. Christensen
EREben L. Rosenthal
Eben L. Rosenthal
JMJ. Scott Magnuson
J. Scott Magnuson

12 November 2010 in Head & Neck
Verified
Journal Article
Closed access
PDF file
JAJulie A. Ames
Julie A. Ames
LKLucy Hynds Karnell
Lucy Hynds Karnell
AGAnjali K. Gupta
Anjali K. Gupta
TCTodd C. Coleman
Todd C. Coleman
MKMichael P. Karnell
Michael P. Karnell
GFGerry F. Funk
Gerry F. Funk

24 December 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
LKLucy Hynds Karnell
Lucy Hynds Karnell
SSSteven M. Sperry
Steven M. Sperry
CACarryn M. Anderson
Carryn M. Anderson
NPNitin A. Pagedar
Nitin A. Pagedar

15 December 1999 in Cancer
Verified
Journal Article
Open access
PDF file
LDLouis F. Diehl
Louis F. Diehl
LKLucy Hynds Karnell
Lucy Hynds Karnell
HMHerman R. Menck
Herman R. Menck
BACKGROUND The natural history of chronic lymphocytic leukemia (CLL) is changing, although the reasons (potential changes in the disease's biology or in patterns in patient characteristics, treatment, or referral) are unclear. METHODS This report uses National Cancer Data Base (NCDB) data, which reflect a hospital‐based patient population from a broad spectrum of hospitals in the United States. Age, gender, race/ethnicity, income, treatment, overall survival, and relative survival were evaluated according to time period (1985–1990 and 1991–1995). Comparisons were made with U.S. population figures for 1990 and with series published over the last 70 years. RESULTS CLL comprised 22.6% of the 108,396 cases of leukemia in the data base. The risk of developing CLL increased progressively with age and did not plateau; the average age was 69.6 years. At the time of initial diagnosis, 60.5% of patients received no treatment (this proportion increased from 58.1% to 62.7% between the 2 time periods). Overall survival was 48.2% at 5 years and 22.5% at 10 years. The 5‐year relative survival was 69.5%, 72.2%, 63.1%, and 41.7% for age groups <40, 40–59, 60–79, and 80+ years, respectively; these rates indicated that CLL, and not comorbid disease, caused the greatest percentage of deaths. CONCLUSIONS The risk of developing CLL increases progressively with age without plateauing and is 2.8 times higher for older men than for older women. There is an increasing trend toward no treatment at the time of initial diagnosis. Long term overall survival of CLL patients is poor. CLL is a more fatal disease among older individuals because of the disease itself, not because of comorbid conditions. Cancer 1999;86:2684–92. © 1999 American Cancer Society.